Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 180

Similar articles for PubMed (Select 18157835)

1.

Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.

Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM, Lee WM, Ghany MG; HALT-C Trial Group.

Hepatology. 2008 Feb;47(2):605-12.

PMID:
18157835
2.

Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.

Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE; HALT-C Trial Group.

Control Clin Trials. 2004 Oct;25(5):472-92.

PMID:
15465617
3.

Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Lok AS, Everhart JE, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Ghany MG, Morishima C; HALT-C Trial Group.

Clin Gastroenterol Hepatol. 2007 Feb;5(2):245-54.

PMID:
17296533
4.

Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.

Senturk H, Tahan V, Canbakan B, Uraz S, Ulger Y, Ozaras R, Tabak F, Mert A, Ozbay G.

Neth J Med. 2008 May;66(5):191-5.

5.
6.

Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy.

Hsu CS, Liu CH, Liu CJ, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2009;14(1):45-54.

PMID:
19320236
7.

Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin.

Biermer M, Berg T.

Gastroenterology. 2009 Jul;137(1):390-1. doi: 10.1053/j.gastro.2009.02.087. Epub 2009 May 30. No abstract available.

PMID:
19486953
8.

[Results of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in clinical practice: a 5-year experience].

Vergara M, Gallach M, Dalmau B, Gil M, Miquel M, Rudi N, Gavarro A, Cebollero A, Masip M, Real J.

Gastroenterol Hepatol. 2008 May;31(5):274-9. Spanish.

PMID:
18448055
9.

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.

Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM.

J Gastroenterol Hepatol. 2008 Jun;23(6):861-6. doi: 10.1111/j.1440-1746.2008.05397.x. Epub 2008 Apr 19.

PMID:
18422960
10.

[Goals of treatment, indication, and treatment for chronic hepatitis C].

Paik SW.

Korean J Gastroenterol. 2008 Jun;51(6):368-71. Review. Korean.

11.

[Treatment of chronic hepatitis C virus infection in hemodialysis patients].

Kaya S.

Mikrobiyol Bul. 2008 Jul;42(3):525-34. Review. Turkish.

PMID:
18822900
12.

Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.

Giordanino C, Bugianesi E, Smedile A, Ciancio A, Abate ML, Olivero A, Pellicano R, Cassader M, Gambino R, Bo S, Ciccone G, Rizzetto M, Saracco G.

Am J Gastroenterol. 2008 Oct;103(10):2481-7. doi: 10.1111/j.1572-0241.2008.02002.x. Epub 2008 Aug 8.

PMID:
18702647
13.

The effect of early virological response in health-related quality of life in HCV-infected patients.

Quarantini LC, Miranda-Scippa A, Batista-Neves S, Galvão-de-Almeida A, Lacerda AL, Moriyama TS, Sampaio AS, Melcop AC, Schinoni MI, de Oliveira IR, Paraná R, Bressan RA.

J Med Virol. 2008 Mar;80(3):419-23. doi: 10.1002/jmv.21094.

PMID:
18205211
14.

Virological response of Tunisians patients treated by peginterferon plus ribavirin for chronic hepatitis C: a preliminary study.

Belhadj N, Houissa F, Elloumi H, Ouakaa A, Gargouri D, Romani M, Kilani A, Kochlef A, Kharrat J, Ghorbel A.

Tunis Med. 2008 Apr;86(4):341-5.

PMID:
19476135
15.

HCV virological response during treatment of chronic hepatitis C is associated with liver histological improvement in patients with HCV/HIV co-infection.

Castro G, Ramalho LN, Zucoloto S, Martinelli Ade L, Figueiredo JF.

Braz J Infect Dis. 2008 Jun;12(3):180-5.

16.

Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients.

del Valle J, Mira JA, de los Santos I, López-Cortés LF, Merino D, Rivero A, Girón JA, Ríos-Villegas MJ, González-Serrano M, Collado A, García-García JA, Pineda JA.

AIDS. 2008 May 11;22(8):923-30. doi: 10.1097/QAD.0b013e3282ff8ad3.

PMID:
18453851
17.

Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels.

Iwasa M, Hara N, Miyachi H, Tanaka H, Takeo M, Fujita N, Kobayashi Y, Kojima Y, Kaito M, Takei Y.

J Viral Hepat. 2009 Oct;16(10):716-23. doi: 10.1111/j.1365-2893.2009.01119.x. Epub 2009 Mar 3.

PMID:
19302338
18.

Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol.

Caroleo B, Gallelli L, Staltari O, De Sarro G, Guadagnino V.

Intervirology. 2008;51(6):407-9. doi: 10.1159/000205266. Epub 2009 Mar 4.

PMID:
19258719
19.

Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection.

Iacobellis A, Andriulli A.

Expert Opin Pharmacother. 2009 Aug;10(12):1929-38. doi: 10.1517/14656560903066811. Review.

PMID:
19563272
20.

Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.

Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, Schöniger-Hekele M, Holzmann H, Steindl-Munda P.

Gastroenterology. 2008 Nov;135(5):1561-7. doi: 10.1053/j.gastro.2008.07.072. Epub 2008 Aug 3.

PMID:
18771667
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk